China Hastens New Drug Development, Bayer Starts 20 New Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
Bayer HealthCare China President Li Xilie, revealed April 28 that Bayer Schering Pharma started 20 new drug clinical trials in China last year
You may also be interested in...
Bayer Schering Forges Women's Health Research Partnership With Beijing's People's Liberation Army General Hospital
PERTH, Australia - Bayer Schering Pharma AG has forged a long-term strategic research partnership in the area of women's health with the People's Liberation Army General Hospital, known as 301 Hospital, in Beijing
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.